Chiasma, Inc. (CHMA)
| Market Cap | 242.78M |
| Revenue (ttm) | 142,000 |
| Net Income (ttm) | -67.02M |
| Shares Out | 61.46M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $4.23 |
| Previous Close | $4.07 |
| Change ($) | 0.16 |
| Change (%) | 3.93% |
| Day's Open | 4.07 |
| Day's Range | 4.05 - 4.29 |
| Day's Volume | 719,192 |
| 52-Week Range | 2.98 - 7.04 |
Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience
MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers
The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), positio...
Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously inje...
Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.
NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial
NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...
Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript
L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September
NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitm...
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal F...
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral thera...
Chiasma advances U.S. commercial launch originally planned for fourth quarter Chiasma advances U.S. commercial launch originally planned for fourth quarter
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therap...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q2 2020 Results - Earnings Call Transcript
MYCAPSSA® U.S. commercial launch planned for the fourth quarter
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=1...
The company announced the pricing of a public offering of common stock.
NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its ...
Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its ...
Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved
Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript
NEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challeng...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript
FDA sets PDUFA date of June 26, 2020
MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...
WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...
Chiasma, Inc. (CHMA) CEO Raj Kannan on Q3 2019 Results - Earnings Call Transcript
WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...
Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
When we first visited all-or-nothing drug delivery concern and busted IPO Chiasma last October, it had just completed enrollment of two Phase 3 trials for the treatment of acromegaly.
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious c...
WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious c...
Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chiasma's (CHMA) CEO Raj Kannan on Q2 2019 Results - Earnings Call Transcript
Chiasma announced positive results from its Phase 3 CHIASMA OPTIMAL study in that all primary and secondary endpoints were met.
Further expanding his holdings in the health care space, billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.24% stake in biotech company C...
CHMA chart shows a strong bullish trend in the last one year, however, the stock is down strongly in the past few days after the end of profit taking session.
Thinly-traded micro-cap biotech Chiasma Inc (NASDAQ: CHMA) is advancing strongly in reaction to a clinical trial readout from the company.
Chiasma is a small-cap biotech focusing on developing of oral formulation of the existing drug for acromegaly (octreotide) and attacking a $810m market.
Chiasma (CHMA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
As of late, it has definitely been a great time to be an investor Chiasma.
About CHMA
Chiasma, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
| Industry Biotechnology | IPO Date Jul 16, 2015 |
| CEO Raj Kannan | Employees 85 |
| Stock Exchange NASDAQ | Ticker Symbol CHMA |
Analyst Forecasts
According to 5 analysts, the average rating for Chiasma stock is "Strong Buy." The 12-month stock price forecast is 13.20, which is an increase of 212.06% from the latest price.